Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vito Barbieri

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Journal of Clinical Pharmacology|March 24, 2010
Capecitabine-induced, rapid decrease of renal function due to drug dispensing error in a hospital pharmacyGiulio Di Mizio, Luca Gallelli, Vito Barbieri, et al.
Current Oncology (Toronto, Ont.)|November 24, 2023
Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel DiscussionCesare Gridelli, Marcello Tiseo, Diego Luigi Cortinovis, et al.
Journal of Molecular Medicine (Berlin, Germany)|June 16, 2007
IL-2 signals through Sgk1 and inhibits proliferation and apoptosis in kidney cancer cellsRosario Amato, Miranda Menniti, Valter Agosti, et al.
Expert Review of Respiratory Medicine|January 15, 2019
Diagnosis and first-line treatment of non-small cell lung cancer in the era of novel immunotherapy: recommendations for clinical practiceFilippo De Marinis, Massimo Barberis, Vito Barbieri, et al.
Frontiers in Immunology|October 9, 2025
Do age and performance status matter? A systematic review and network meta-analysis of immunotherapy studies in untreated advanced/metastatic non-oncogene addicted NSCLCMaria Anna Siciliano, Maria d'Apolito, Teresa Del Giudice, et al.
High-Throughput|October 31, 2018
From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision OncologyMaria Eugenia Gallo Cantafio, Katia Grillone, Daniele Caracciolo, et al.
Oncology Reports|March 27, 2012
Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trialsDomenico Ciliberto, Ubaldo Prati, Laura Roveda, et al.
Critical Reviews in Oncology/Hematology|October 9, 2018
The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysisNicoletta Staropoli, Domenico Ciliberto, Teresa Del Giudice, et al.
Oncoimmunology|May 17, 2017
A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumorsRiccardo Turrini, Anna Merlo, Debora Martorelli, et al.
EJNMMI Physics|November 13, 2024
Comparison of the dosimetry and cell survival effect of <sup>177</sup>Lu and <sup>161</sup>Tb somatostatin analog radiopharmaceuticals in cancer cell clusters and micrometastasesLaura De Nardo, Sara Santi, Anna Dalla Pietà, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Journal of Clinical Pharmacology|March 24, 2010
Capecitabine-induced, rapid decrease of renal function due to drug dispensing error in a hospital pharmacyGiulio Di Mizio, Luca Gallelli, Vito Barbieri, et al.
Current Oncology (Toronto, Ont.)|November 24, 2023
Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel DiscussionCesare Gridelli, Marcello Tiseo, Diego Luigi Cortinovis, et al.
Journal of Molecular Medicine (Berlin, Germany)|June 16, 2007
IL-2 signals through Sgk1 and inhibits proliferation and apoptosis in kidney cancer cellsRosario Amato, Miranda Menniti, Valter Agosti, et al.
Expert Review of Respiratory Medicine|January 15, 2019
Diagnosis and first-line treatment of non-small cell lung cancer in the era of novel immunotherapy: recommendations for clinical practiceFilippo De Marinis, Massimo Barberis, Vito Barbieri, et al.
Frontiers in Immunology|October 9, 2025
Do age and performance status matter? A systematic review and network meta-analysis of immunotherapy studies in untreated advanced/metastatic non-oncogene addicted NSCLCMaria Anna Siciliano, Maria d'Apolito, Teresa Del Giudice, et al.
High-Throughput|October 31, 2018
From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision OncologyMaria Eugenia Gallo Cantafio, Katia Grillone, Daniele Caracciolo, et al.
Oncology Reports|March 27, 2012
Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trialsDomenico Ciliberto, Ubaldo Prati, Laura Roveda, et al.
Critical Reviews in Oncology/Hematology|October 9, 2018
The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysisNicoletta Staropoli, Domenico Ciliberto, Teresa Del Giudice, et al.
Oncoimmunology|May 17, 2017
A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumorsRiccardo Turrini, Anna Merlo, Debora Martorelli, et al.
EJNMMI Physics|November 13, 2024
Comparison of the dosimetry and cell survival effect of <sup>177</sup>Lu and <sup>161</sup>Tb somatostatin analog radiopharmaceuticals in cancer cell clusters and micrometastasesLaura De Nardo, Sara Santi, Anna Dalla Pietà, et al.
Pageof 5